The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to bempegaldesleukin (NKTR-214; Nektar Therapeutics and Bristol-Myers Squibb) in combination with nivolumab (Opdivo; Bristol-Myers Squibb) for the treatment of patients with previously untreated unresectable or metastatic melanoma.
Cutaneous SCC risk reduced for highest versus lowest quintile of vitamin A, retinol, some carotenoids.
Researchers sought to determine the risk of disease recurrence in patients with localized melanoma at high risk of disease metastasis.
With the exception of those enrolled in a clinical trial, all patients in this study received systemic monotherapy as first-line treatment of metastatic melanoma.
Calculated tumor area is a novel, microscopic feature and a two-dimensional surrogatefor tumor size.
Approximately one half of all biopsied/excised lesions from patients who have sun-damaged skin are nonmelanocytic.
A comparison of AEDs finds that while most were not associated with skin cancer, carbamazepine and lamotrigine were associated with squamous cell carcinoma.
In the modern era of therapeutic agents, metastasectomy was still associated with improved survival outcomes for patients with stage IV melanoma.
Secondary end points were not significantly different between the 2 groups, including overall survival.
The combination of ipilimumab and nivolumab resulted in a higher rate of objective remissions compared with ipilimumab alone.
Adjuvant ipilimumab may improve overall survival in patients with resected high-risk melanoma.
Researchers concluded that the ability to achieve pCR correlated to improved recurrence-free survival in melanoma.
Researchers from the FDA analyzed 10 RCTs conducted in patients with unresectable or metastatic melanoma who were treated with 1 of 3 drug types.
The identification of biomarkers of response and resistance to immune checkpoint inhibitors remains an active area of research.
New data revealed an association between low baseline IL-6 level and improved survival in patients across all 3 arms of CheckMate 067.
More than 60 percent of products do not provide adequate sun protection, contain potentially harmful chemicals.
Researchers suggest using novel therapies that act by a distinct mechanism of action to boost durable response rates in patients with treatment-resistant metastatic melanoma.
In this study, approximately one-third of patients receiving the combination of a BRAF and a MEK inhibitor following anti-PD-1 therapy required hospitalization due to an adverse event.
Female gender and ulceration were among the variables found to be predictive of a positive CLND in patients with melanoma characterized by a positive sentinel lymph node.
A retrospective study identified incidence of and treatment trends for anorectal mucosal melanoma tumors.